ABOUT THIS EPISODE
At TCT 2025, Dr Nadira Hamid (Minneapolis Heart Institute, US) and Dr. Rahul P. Sharma (Stanford University, US) review the late-breaking trial data shaping the future of structural heart disease.
The discussion highlights real-world results from TRISCEND and TRILUMINATE in tricuspid disease, 7-year PARTNER 3 durability outcomes in TAVR, national prevalence insights from the PREVUE-VALVE study, and new frontiers in mitral intervention with SUMMIT MAC. Together, they examine what the evidence means for safety, durability, patient selection, and clinical adoption.
01:05 – Tricuspid Therapies
Late-breaking data from Triluminate (TriClip) and Tricend/Evoke: real-world outcomes, bleeding reduction, pacemaker trends, and patient selection.
06:40 – Aortic Valve Durability
PARTNER 7-year outcomes: TAVR vs. SAVR, valve performance over time, implications for younger/lower-risk patients, and evolving device technology.
12:55 – Valvular Disease Prevalence
Insights from the PREVUE-VALVE: first nationwide prevalence data, under-treatment of severe disease, and role of AI in early detection.
17:30 – Mitral Valve Advances
Landmark trials: SUMMIT Trial (MAC population) and first-in-human Sapien M3 transseptal TMVR. Key outcomes, screen failure rates, and implications for clinical adoption.
24:50 – Future of Structural Heart Interventions
Patient-first approach, expanding treatment options, and importance of durability and early diagnosis.
For more content from TCT 2025 head to the Late-breaking Science Video Collection.
Editor: Mirjam Boros
Videographer: Tom Green and Dan Brent
Support: This is an independent video produced by Radcliffe Cardiology.
The discussion highlights real-world results from TRISCEND and TRILUMINATE in tricuspid disease, 7-year PARTNER 3 durability outcomes in TAVR, national prevalence insights from the PREVUE-VALVE study, and new frontiers in mitral intervention with SUMMIT MAC. Together, they examine what the evidence means for safety, durability, patient selection, and clinical adoption.
01:05 – Tricuspid Therapies
Late-breaking data from Triluminate (TriClip) and Tricend/Evoke: real-world outcomes, bleeding reduction, pacemaker trends, and patient selection.
06:40 – Aortic Valve Durability
PARTNER 7-year outcomes: TAVR vs. SAVR, valve performance over time, implications for younger/lower-risk patients, and evolving device technology.
12:55 – Valvular Disease Prevalence
Insights from the PREVUE-VALVE: first nationwide prevalence data, under-treatment of severe disease, and role of AI in early detection.
17:30 – Mitral Valve Advances
Landmark trials: SUMMIT Trial (MAC population) and first-in-human Sapien M3 transseptal TMVR. Key outcomes, screen failure rates, and implications for clinical adoption.
24:50 – Future of Structural Heart Interventions
Patient-first approach, expanding treatment options, and importance of durability and early diagnosis.
For more content from TCT 2025 head to the Late-breaking Science Video Collection.
Editor: Mirjam Boros
Videographer: Tom Green and Dan Brent
Support: This is an independent video produced by Radcliffe Cardiology.
English
United States
IN THIS EPISODE
TRANSCRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
SEARCH PAST EPISODES
Search past episodes of The Radcliffe Cardiology Podcast.
OTHER EPISODES IN THIS PODCAST
How can mentorship shape a career in cardiology, and what can we learn from a pioneer in the field?
Join Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, SA) and Dr Julia Grapsa (Guy's and St Thomas' NHS Foundation Trust, UK) as they interview Professor Eugene Braunwald, Distinguished Hersey P…
What is the reasoning behind the porosity of data when it comes to CV outcomes in women?
Diversity, Inclusion and Equity in Cardiology hosts, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, Jeddah, SA) and Dr Julia Grapsa (Guy's and St Thomas' NHS Foundation Trust, London, UK) are joined by P…
How can institutions overcome toxic workplace behaviours, and why is it important?
Diversity, Inclusion and Equity in Cardiology hosts, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, Jeddah, SA) and Dr Julia Grapsa (Guy's and St Thomas' NHS Foundation Trust, London, UK) are joined by Prof Ma…
This episode examines the multidisciplinary team (MDT) in HCM, exploring its ideal structure, function, and real-world challenges. Prof Juan Pablo Kaski is joined by Dr Elena Biagini and Dr Jodie Ingles to share insights from their work on the 2023 ESC guidelines and MDT care.
Introducing our new podcast series, Diversity, Inclusion and Equity in Cardiology with hosts, Dr Mirvat Alasnag and Dr Julia Grapsa.
Starting with Prof Braunwald, this series features expert guests who discuss topics from navigating challenging work environments to the future legacy for women in c…
Disclaimer: The podcast and artwork embedded on this page are from The Radcliffe Cardiology Podcast, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.
EDIT
Thank you for helping to keep the podcast database up to date.
